Trial Profile

An Observational, Non-interventional, Study of Patients With Hereditary Angioedema in the United States and Canada (EMPOWER Study)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 27 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lanadelumab (Primary)
Indications Hereditary angioedema
Focus Therapeutic Use
Acronyms EMPOWER

Most Recent Events

26 Feb 2024 Results (n=113) assessing Long-Term Effectiveness and Safety of Lanadelumab in Patients With Hereditary Angioedema From the United States and Canada presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
29 Mar 2023 Status changed from active, no longer recruiting to completed.
27 Feb 2023 24-month Interim results presented at the 2023 Annual Meeting of the American Academy of Allergy, Asthma and Immunology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com